# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-26-270386
Filing Date
2026-06-15
Accepted
2026-06-15 09:16:50
Documents
79
Period of Report
2026-04-30

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | engn-20260430.htm iXBRL | 10-Q | 2492669
2 | EX-10.2 | engn-ex10_2.htm | EX-10.2 | 131072
3 | EX-10.3 | engn-ex10_3.htm | EX-10.3 | 156313
4 | EX-31.1 | engn-ex31_1.htm | EX-31.1 | 23166
5 | EX-31.2 | engn-ex31_2.htm | EX-31.2 | 22358
6 | EX-32.1 | engn-ex32_1.htm | EX-32.1 | 11924
7 | EX-32.2 | engn-ex32_2.htm | EX-32.2 | 11914
| Complete submission text file | 0001193125-26-270386.txt |  | 11789244

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
8 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | engn-20260430.xsd | EX-101.SCH | 1808708
83 | EXTRACTED XBRL INSTANCE DOCUMENT | engn-20260430_htm.xml | XML | 2220722

Mailing Address 4868 RUE LEVY, SUITE 220 SAINT-LAURENT Quebec, Canada
Business Address 4868 RUE LEVY, SUITE 220 SAINT-LAURENT Quebec, Canada (514) 332-4888
enGene Therapeutics Inc. (Filer) CIK: 0001980845 (see all company filings)

EIN.: 000000000 | State of Incorp.: Z4 | Fiscal Year End: 1031
Type: 10-Q | Act: 34 | File No.: 001-41854 | Film No.: 261089205
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)